Evidence map›Paper›PMID 41809256›Full record

ArticleAsian journal of pharmaceutical sciences2025

Overcoming corneal barriers: Posaconazole loaded cationic surfactant vesicles for enhanced ocular permeability and anti-fungal efficacy.

Kshitija M Phatak, Ankita N Yawalkar, Sushant S Sole, Pradeep R Vavia

Abstract read
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kshitija M PhatakDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, India.
Ankita N YawalkarDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, India.
Sushant S SoleDepartment of Veterinary Pharmacology and Toxicology, Mumbai Veterinary College, Mumbai 400012, India.
Pradeep R VaviaDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posaconazole (PCZ) is a broad-spectrum anti-fungal drug approved by FDA and currently used off-label for the treatment of fungal keratitis (FK). Although ocular route serves as the most bioavailable route for treating FK, delivery of PCZ to the eye remains a challenge due to poor permeation though the cornea and rapid elimination from the eye. Here we outline a comprehensive formulation development process, beginning with

Indexed as

CationicFungal keratitisMucoadhesiveOcularPosaconazoleSurfactant vesicles

Identifiers

PMID41809256
PMCPMC12538011

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.